BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33208882)

  • 1. TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1.
    Caliò A; Harada S; Brunelli M; Pedron S; Segala D; Portillo SC; Magi-Galluzzi C; Netto GJ; Mackinnon AC; Martignoni G
    Mod Pathol; 2021 Apr; 34(4):842-850. PubMed ID: 33208882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic and Molecular Analysis of the TFEB Fusion Variant Reveals New Members of TFEB Translocation Renal Cell Carcinomas (RCCs): Expanding the Genomic Spectrum.
    Xia QY; Wang XT; Fang R; Wang Z; Zhao M; Chen H; Chen N; Teng XD; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Am J Surg Pathol; 2020 Apr; 44(4):477-489. PubMed ID: 31764220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Renal cell carcinoma with t(6;11)(p21.2;q13)/MALAT1-TFEB fusion: a clinical and pathological analysis].
    Xia Q; Shi S; Shen Q; Wei X; Wang X; Ma H; Lu Z; Zhou X; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):895-9. PubMed ID: 26888508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Tale of 2 Morphologies: Diagnostic Pitfalls in
    Sharma AE; Parilla M; Wanjari P; Segal JP; Antic T
    Int J Surg Pathol; 2021 Feb; 29(1):21-29. PubMed ID: 32886007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.
    Caliò A; Brunelli M; Segala D; Pedron S; Tardanico R; Remo A; Gobbo S; Meneghelli E; Doglioni C; Hes O; Zampini C; Argani P; Martignoni G
    Mod Pathol; 2018 Mar; 31(3):474-487. PubMed ID: 29052596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization.
    Rao Q; Liu B; Cheng L; Zhu Y; Shi QL; Wu B; Jiang SJ; Wang Y; Wang X; Yu B; Zhang RS; Ma HH; Lu ZF; Tu P; Wang JD; Zhou XJ
    Am J Surg Pathol; 2012 Sep; 36(9):1327-38. PubMed ID: 22895266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translocation carcinomas of the kidney.
    Argani P
    Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.
    Pei J; Cooper H; Flieder DB; Talarchek JN; Al-Saleem T; Uzzo RG; Dulaimi E; Patchefsky AS; Testa JR; Wei S
    Mod Pathol; 2019 May; 32(5):710-716. PubMed ID: 30622287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
    Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
    Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity.
    Argani P; Reuter VE; Zhang L; Sung YS; Ning Y; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Nov; 40(11):1484-1495. PubMed ID: 27565001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations.
    Caliò A; Brunelli M; Segala D; Pedron S; Doglioni C; Argani P; Martignoni G
    Mod Pathol; 2019 Feb; 32(2):258-268. PubMed ID: 30206412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
    Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
    Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanotic MiT family translocation neoplasms: Expanding the clinical and molecular spectrum of this unique entity of tumors.
    Saleeb RM; Srigley JR; Sweet J; Doucet C; Royal V; Chen YB; Brimo F; Evans A
    Pathol Res Pract; 2017 Nov; 213(11):1412-1418. PubMed ID: 28969862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas.
    Harada S; Caliò A; Janowski KM; Morlote D; Rodriguez Pena MD; Canete-Portillo S; Harbi D; DeFrank G; Magi-Galluzzi C; Netto GJ; Martignoni G; Mackinnon AC
    Mod Pathol; 2021 Nov; 34(11):2055-2063. PubMed ID: 34148064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum.
    Argani P; Yonescu R; Morsberger L; Morris K; Netto GJ; Smith N; Gonzalez N; Illei PB; Ladanyi M; Griffin CA
    Am J Surg Pathol; 2012 Oct; 36(10):1516-26. PubMed ID: 22892601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
    Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
    Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.
    Argani P; Laé M; Hutchinson B; Reuter VE; Collins MH; Perentesis J; Tomaszewski JE; Brooks JS; Acs G; Bridge JA; Vargas SO; Davis IJ; Fisher DE; Ladanyi M
    Am J Surg Pathol; 2005 Feb; 29(2):230-40. PubMed ID: 15644781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.
    Wyvekens N; Rechsteiner M; Fritz C; Wagner U; Tchinda J; Wenzel C; Kuithan F; Horn LC; Moch H
    Virchows Arch; 2019 May; 474(5):625-631. PubMed ID: 30706129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
    Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
    Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
    Martignoni G; Gobbo S; Camparo P; Brunelli M; Munari E; Segala D; Pea M; Bonetti F; Illei PB; Netto GJ; Ladanyi M; Chilosi M; Argani P
    Mod Pathol; 2011 Oct; 24(10):1313-9. PubMed ID: 21602817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.